Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
暂无分享,去创建一个
C. Bloomfield | J. Byrd | R. Larson | K. Mrózek | R. Dodge | S. Patil | R. Mayer | A. Carroll | P. Koduru | R. Stone | D. Arthur | F. Davey | Joseph O. Moore | M. Watson | E. Feldman | C. Schiffer | M. Pettenati | Kathleen W. Rao | C. Edwards | J. Moore | K. Rao